RegenETP, Inc. Stock

Stocks

25-09-02	PolarityBio Announces Launch of Expanded Access Treatment Protocol to Provide Continued Access to SkinTE for Patients with Wagner 1 Diabetic Foot Ulcers	CI
25-08-26	PolarityBio Completes Enrollment in the Phase III Pivotal Study of SkinTE for Diabetic Foot Ulcers	CI
24-05-19	RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC	CI
24-02-26	PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers	CI
23-08-18	PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer	CI
23-08-18	PolarityTE, Inc. Announces Executive Changes	CI
23-08-18	PolarityTE, Inc. has Changed its Name to RegenETP, Inc	CI
23-08-14	Grander Acquisition LLC completed the acquisition of Substantially all of the assets of PolarityTE, Inc..	CI
23-08-01	PolarityTE, Inc. Announces the Resignation of Jeff Dyer from the Company's Board of Directors	CI
23-06-15	PolarityTE, Inc.(OTCPK:PTEI.Q) dropped from NASDAQ Composite Index	CI
23-06-13	PolarityTE, Inc.(NasdaqCM:PTE) dropped from S&P TMI Index	CI
23-06-06	Grander Acquisition LLC entered into a stalking horse asset purchase agreement to acquire Substantially all of the assets of PolarityTE, Inc. for $6.5 million.	CI
23-05-12	PolarityTE, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

22-12-28	Northland Securities Adjusts Price Target on PolarityTE to $1 From $1.25, Maintains Outperform Rating	MT
22-03-31	Cantor Fitzgerald Downgrades PolarityTE to Neutral From Overweight, Adjusts Price Target to $1 From $2.50	MT

23-08-15	PolarityTE : Acquisition/Asset Disposal - Form 8-K	PU
23-06-07	POLARITYTE, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
23-06-07	POLARITYTE, INC. : Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
23-04-26	POLARITYTE, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
23-03-27	POLARITYTE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ

1 day

-8.24%

Manager	Title	Age	Since
Nikolai Sopko CTO	Chief Tech/Sci/R&D Officer	-	-
Ryan Mathis CTO	Chief Tech/Sci/R&D Officer	-	2021-08-31
Stephen Milner CTO	Chief Tech/Sci/R&D Officer	-	2017-03-29

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/26/23	Jeffrey Dyer	Other	Director	11,872	0.1641%
1/26/23	Jeffrey Dyer	Free	Director	42,986	0.5942%
1/12/23	Christian Nolet	Fiscal year	Director	39,575	0.5470%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENETP, INC.	-8.24%	+0.65%	-	-	1.12M
CHURCHILL CAPITAL CORP XI	-6.71%	-9.82%	-	-	872M
CENTIEL AG	-3.24%	+0.31%	+285.88%	-71.97%	681M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	0.00%	-0.10%	-	-	645M
BAIN CAPITAL GSS INVESTMENT CORP.	+0.59%	+0.59%	-	-	598M
CHURCHILL CAPITAL CORP XII	-0.74%	0.00%	-	-	599M
CANTOR EQUITY PARTNERS IV, INC.	-0.10%	-0.29%	-	-	594M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-0.26%	-0.86%	-	-	570M
CHURCHILL CAPITAL CORP XIII	-0.10%	-0.38%	-	-	508M
Average	-2.00%	-0.05%	+285.88%	-71.97%	633.36M
Weighted average by Cap.	-1.56%	-0.23%	+285.88%	-71.97%